Orgenesis Inc. (ORGS) EPS Estimated At $-0.09

September 15, 2018 - By Palma Niemeyer

Orgenesis Inc. (NASDAQ:ORGS) Logo

Analysts expect Orgenesis Inc. (NASDAQ:ORGS) to report $-0.09 EPS on October, 16.After having $-0.20 EPS previously, Orgenesis Inc.’s analysts see -55.00 % EPS growth. The stock increased 5.28% or $0.28 during the last trading session, reaching $5.58. About 38,167 shares traded or 11.27% up from the average. Orgenesis Inc. (NASDAQ:ORGS) has risen 26.19% since September 16, 2017 and is uptrending. It has outperformed by 10.57% the S&P500.

Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. The company has market cap of $83.64 million. It operates through two divisions, Contract Development and Manufacturing Organizations and Cellular Therapy (CT) Business. It currently has negative earnings. The CDMO segment specializes in cell therapy development for advanced medicinal products.

Another recent and important Orgenesis Inc. (NASDAQ:ORGS) news was published by which published an article titled: “Orgenesis Announces Collaboration with Ben-Gurion University to Develop and Commercialize a Novel Scaffold …” on August 23, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.